1 / 16

Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1

Laryngoprotect-Study R. Knecht et al. Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1 5-FU 1000mg/m 2 d1-4. Radiochemotherapy 70 Gy + Cisplatin 100 mg /m 2 d1, 22, 43. Regions and stages in %. 55%. T/N. N 0. N 2. N 3. N 1. .

kimberly
Download Presentation

Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Laryngoprotect-Study R. Knecht et al. Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m2 d1 Cisplatin 100mg/m2 d1 5-FU 1000mg/m2 d1-4 Radiochemotherapy 70 Gy + Cisplatin 100 mg /m2 d1, 22, 43

  2. Regions and stages in % 55% T/N N0 N2 N3 N1  T2 4 4 13 21 2 3 3 8 2 3 - 5 15 35 50 100 7 24% 25 34 T3 T4 66  n=103 Stage II Stage III Stage IV 21%

  3. Toxicity (WHO Grad III / IV) Radio- chemotherapy Induction chemotherapy Renal 25% 4% Afebrile Neutropenia 95% 47% Nausea/Vomiting 25% 20% Mucositis 10% 43% Sensory Neuropathy 10% 5%

  4. Results after TPF - Polychemotherapy (3 Cycles) RR CR Supraglottis Glottis Hypopharynx  76% 73% 92% 79% 41% 53% 54% 47%

  5. Results after TPF - Polychemotherapy (3 Cycles) post prae S. A., T3N3M0

  6. Results after TPF - Polychemotherapy (3 Cycles) prae B. W., T2N1M0 post

  7. Results after TPF - Polychemotherapy(3 Cycles) prae B. W., T2N1M0 post

  8. Results after TPF - Polychemotherapy (3 Cycles) prae M. B., T2N1M0 post

  9. Results after TPF - Polychemotherapy (3 Cycles) post prae B. H., T2N2bM0

  10. Results after TPF - Polychemotherapy (3 Cycles) post prae G. H., T2N2bM0

  11. Results after TPF - Polychemotherapy (3 Cycles) post prae J. H., T2N2bM0

  12. Results Hypopharynx 2 years Laryngoprotect n = 103 Induction chemotherapy 3 Cycles Cisplatin (100mg/m2) 5 Fluorouracil (4000mg/m2) Docetaxel (75mg/m2) Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m2) Larynx preservation Disease free surv. Distant metastasis Survival 74% 75% 2% 93% Knecht R . et al. (2004)JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559

  13. Results Larynx 2 years Laryngoprotect n = 103 Induktion chemotherapy 3 Cycles Cisplatin (100mg/m2) 5 Fluorouracil (4000mg/m2) Docetaxel (75mg/m2) Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m2) Larynx preservation Disease free surv. Distant metastasis Survival 91% 85% 0% 94% Knecht R . et al. (2004)JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559

  14. Results Larynx 2 years RTOG 91-11 n = 172 Laryngoprotect n = 103 Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m2) Induction chemotherapy 3 Cycles Cisplatin (100mg/m2) 5 Fluorouracil (4000mg/m2) Docetaxel (75mg/m2) Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m2) Larynx preservation Disease free surv. Distant metastasis Survival 91% 85% 0% 94% 88% 61% 8% 74% Knecht R . et al. (2004)JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559

  15. Laryngoprotect 2 2 Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m2) Induction chemotherapy 3 Cycles Cisplatin (100mg/m2) 5 Fluorouracil (4000mg/m2) Docetaxel (75mg/m2) Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m2)

  16. EGFR-Antibody Neoadjuvant Primary Therapy Stage III/IV Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m2 d1 Cisplatin 100mg/m2 d1 5-FU 1000mg/m2 d1-4 Cetuximab (400 mg d1; 250mg ab d8 wöchtl) Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m2 d1 Cisplatin 100mg/m2 d1 5-FU 1000mg/m2 d1-4 Radiochemotherapy 70 Gy (2 Gy/d; 5x/week) Cisplatin, (300mg/m2 total) International principal investigator: R. Knecht

More Related